Edelson Richard L
Aaron and Marguerite Lerner Professor and Chairman, Department of Dermatology, Yale University School of Medicine, USA.
Transfus Apher Sci. 2014 Jun;50(3):322-9. doi: 10.1016/j.transci.2013.07.031. Epub 2013 Aug 8.
Extracorporeal photochemotherapy (ECP) is a widely used immunotherapy for cutaneous T cell lymphoma, as well as immunomodulation of graft-versus-host disease (GVHD) and transplanted organ rejection. ECP's mechanism encompasses large-scale physiologic platelet induction of dendritic cells (DCs). The normal bidirectional immunologic talents of DCs likely contribute heavily to ECP's capacity to immunize against tumor antigens, while also suppressing transplant immunopathology. Our understanding of how ECP physiologically induces monocyte-to-DC maturation can enhance the treatment's potency, potentially broaden its use to other cancers and autoimmune disorders and tailor its application to individual patients' diseases. ECP's next decade is filled with promise.
体外光化学疗法(ECP)是一种广泛应用于皮肤T细胞淋巴瘤的免疫疗法,同时也用于移植物抗宿主病(GVHD)和移植器官排斥反应的免疫调节。ECP的作用机制包括通过血小板大规模生理性诱导树突状细胞(DCs)。DCs正常的双向免疫功能可能在很大程度上有助于ECP针对肿瘤抗原进行免疫的能力,同时还能抑制移植免疫病理学。我们对ECP如何生理性诱导单核细胞向DC成熟的理解,能够提高该疗法的效力,有可能将其应用范围扩大到其他癌症和自身免疫性疾病,并根据个体患者的病情进行个性化应用。ECP的未来十年充满希望。